Atara Biotherapeutics (Nasdaq: ATRA) has appointed Cokey Nguyen as its new president and chief executive.
Dr Nguyen, who previously served as the company's chief scientific and technical officer, brings significant experience in cell therapy and oncology to the new position.
His background includes senior roles at Fate Therapeutics (Nasdaq: FATE) and Pfizer (NYSE: PFE), where he led research in bispecific antibodies and immune effector cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze